Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

NCT05605470 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19, SARS CoV 2 Infection

Interventions

BIOLOGICAL: ChulaCov19 BNA159 vaccine (50 mcg)
BIOLOGICAL: Pfizer/BNT vaccine (30 mcg)
BIOLOGICAL: COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)

Sponsor

Technovalia, Pty Ltd

Collaborators

[object Object]
[object Object]
[object Object]